115 related articles for article (PubMed ID: 19706764)
61. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity.
Hahm ER; Singh SV
Mol Cancer Ther; 2007 Oct; 6(10):2686-95. PubMed ID: 17938262
[TBL] [Abstract][Full Text] [Related]
62. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.
Li X; Yokoyama NN; Zhang S; Ding L; Liu HM; Lilly MB; Mercola D; Zi X
Oncotarget; 2015 Dec; 6(39):41809-24. PubMed ID: 26497688
[TBL] [Abstract][Full Text] [Related]
63. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
64. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS
Cancer Res; 2002 Mar; 62(5):1370-6. PubMed ID: 11888907
[TBL] [Abstract][Full Text] [Related]
65. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
Zorn CS; Wojno KJ; McCabe MT; Kuefer R; Gschwend JE; Day ML
Clin Cancer Res; 2007 Apr; 13(7):2136-43. PubMed ID: 17404097
[TBL] [Abstract][Full Text] [Related]
66. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
67. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
68. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
69. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H
Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782
[TBL] [Abstract][Full Text] [Related]
70. Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model.
Zhang J; Ahn KS; Kim C; Shanmugam MK; Siveen KS; Arfuso F; Samym RP; Deivasigamanim A; Lim LH; Wang L; Goh BC; Kumar AP; Hui KM; Sethi G
Antioxid Redox Signal; 2016 Apr; 24(11):575-89. PubMed ID: 26649526
[TBL] [Abstract][Full Text] [Related]
71. A high-fat diet containing lard accelerates prostate cancer progression and reduces survival rate in mice: possible contribution of adipose tissue-derived cytokines.
Cho HJ; Kwon GT; Park H; Song H; Lee KW; Kim JI; Park JH
Nutrients; 2015 Apr; 7(4):2539-61. PubMed ID: 25912035
[TBL] [Abstract][Full Text] [Related]
72. Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate.
Barve A; Khor TO; Hao X; Keum YS; Yang CS; Reddy B; Kong AN
Pharm Res; 2008 Sep; 25(9):2181-9. PubMed ID: 18437538
[TBL] [Abstract][Full Text] [Related]
73. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
74. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).
Wadsworth TL; Worstell TR; Greenberg NM; Roselli CE
Prostate; 2007 May; 67(6):661-73. PubMed ID: 17342743
[TBL] [Abstract][Full Text] [Related]
75. Rutaecarpine administration inhibits cancer cell growth in allogenic TRAMP-C1 prostate cancer mice correlating with immune balance in vivo.
Lin JY; Yeh TH
Biomed Pharmacother; 2021 Jul; 139():111648. PubMed ID: 33945915
[TBL] [Abstract][Full Text] [Related]
76. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
77. Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
Silva RS; Kido LA; Montico F; Vendramini-Costa DB; Pilli RA; Cagnon VHA
Cell Biol Int; 2018 Aug; 42(8):1006-1020. PubMed ID: 29603508
[TBL] [Abstract][Full Text] [Related]
78. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit.
Wang L; Bonorden MJ; Li GX; Lee HJ; Hu H; Zhang Y; Liao JD; Cleary MP; Lü J
Cancer Prev Res (Phila); 2009 May; 2(5):484-95. PubMed ID: 19401524
[TBL] [Abstract][Full Text] [Related]
79. Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice.
Kee K; Foster BA; Merali S; Kramer DL; Hensen ML; Diegelman P; Kisiel N; Vujcic S; Mazurchuk RV; Porter CW
J Biol Chem; 2004 Sep; 279(38):40076-83. PubMed ID: 15252047
[TBL] [Abstract][Full Text] [Related]
80. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
